Gyala Therapeutics has secured €3 million in funding from a syndicate of public and private investors, including CDTI Innovation through its Innvierte program, Nara Capital, and Invivo Partners. This investment will support the advancement of Gyala’s lead CAR-T cell therapy candidate, GYA01, into a Phase I clinical trial planned for 2025 in patients with relapsed or refractory acute myeloid leukemia (AML), a condition with limited treatment options and poor prognosis.
The clinical study will be conducted at two of Spain’s leading academic hospitals: La Fe University Hospital in Valencia and Hospital Clínic de Barcelona.
The financing builds on the company’s initial €1.5 million seed round in 2020, led by Invivo Partners, who remain active partners in Gyala’s long-term growth.
As part of the new investment round, Joan Mercadal, Partner at Nara Capital, will join Gyala’s Board of Directors, further strengthening the company’s strategic and governance capabilities.
This milestone reflects the strong commitment of both public and private stakeholders to Gyala’s mission of advancing next-generation cell therapies and addressing critical unmet medical needs in hematologic malignancies.